Nav: Home

New gene hunt reveals potential breast cancer treatment target

March 08, 2019

Australian and US researchers have developed a way to discover elusive cancer-promoting genes, and have already identified one that appears to promote aggressive breast cancers.

The University of Queensland and Albert Einstein College of Medicine team has developed a statistical approach to reveal many previously hard-to-find genes that contribute to cancer.

Associate Professor Jess Mar, of the University of Queensland's Australian Institute for Bioengineering and Nanotechnology, said the majority of 'oncogenes' identified to date showed up in most patients with a particular cancer type.

"When you average the data across those patients, those common oncogenes tend to stand out, but they don't paint the full picture," Dr Mar said.

"Even if a group of people all have the same type or even subtype of cancer, the molecular makeup of that cancer is different from person to person because the activity of genes vary between people," she said.

"If an oncogene is over-active in one group of patients but inactive in another group, that's statistically harder to see using the tools that we had available.

"If you only look at the average activity of a gene across the two groups, you'd never see the high activity in the first group."

The Oncomix method enables researchers to 'zoom in' on genetic information from cancer patients and identify genes with two distinct 'bumps' of data - low activity in one group of patients but high activity in another.

"We're acknowledging that there is diversity among cancer patients, but we're still looking for trends in the data that pertain to groups of people," Dr Mar said.

Dr Mar and her colleagues used Oncomix to examine breast cancer data from The Cancer Genome Atlas patient database.

They identified five genes that were over-active in a subset of breast cancer patients and followed up on the most promising target, known as CBX2.

"Previous studies have shown that most healthy female tissue has low levels of CBX2 activity, while an aggressive subtype of breast cancer has been shown to have high levels of CBX2 activity," Dr Mar said.

"This suggested a possible link between CBX2 activity and breast cancer, but the nature of that link hadn't been investigated.

"So we switched off the gene in a human breast cancer cell line and this slowed down the growth of those cancer cells, suggesting that CBX2 might promote tumour growth."

Dr Mar said if further tests confirmed that CBX2 was an oncogene, it could be a potential therapeutic drug target for aggressive types of breast cancer.

"This discovery highlights the potential value of the Oncomix approach," Dr Mar said.

"Identifying 'hidden' oncogenes that are unique to smaller groups of cancer patients will open up new therapeutic avenues and move us closer to personalised medicine."

Oncomix is now a publicly-available, open source software tool, and the study is published in the British Journal of Cancer.
-end-


University of Queensland

Related Breast Cancer Articles:

Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
Blood test offers improved breast cancer detection tool to reduce use of breast biopsy
A Clinical Breast Cancer study demonstrates Videssa Breast can inform better next steps after abnormal mammogram results and potentially reduce biopsies up to 67 percent.
Surgery to remove unaffected breast in early breast cancer increases
The proportion of women in the United States undergoing surgery for early-stage breast cancer who have preventive mastectomy to remove the unaffected breast increased significantly in recent years, particularly among younger women, and varied substantially across states.
Breast cancer patients with dense breast tissue more likely to develop contralateral disease
Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer.
Some early breast cancer patients benefit more from breast conservation than from mastectomy
Breast conserving therapy (BCT) is better than mastectomy for patients with some types of early breast cancer, according to results from the largest study to date, presented at ECC2017.
One-third of breast cancer patients not getting appropriate breast imaging follow-up exam
An annual mammogram is recommended after treatment for breast cancer, but nearly one-third of women diagnosed with breast cancer aren't receiving this follow-up exam, according to new findings presented at the 2016 Annual Clinical Congress of the American College of Surgeons.
Low breast density worsens prognosis in breast cancer
Even though dense breast tissue is a risk factor for breast cancer, very low mammographic breast density is associated with a worse prognosis in breast cancer patients.
Is breast conserving therapy or mastectomy better for early breast cancer?
Young women with early breast cancer face a difficult choice about whether to opt for a mastectomy or breast conserving therapy (BCT).
Breast density and outcomes of supplemental breast cancer screening
In a study appearing in the April 26 issue of JAMA, Elizabeth A.
Full dose radiotherapy to whole breast may not be needed in early breast cancer
Five years after breast-conserving surgery, radiotherapy focused around the tumor bed is as good at preventing recurrence as irradiating the whole breast, with fewer side effects, researchers from the UK have found in the large IMPORT LOW trial.

Related Breast Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Changing The World
What does it take to change the world for the better? This hour, TED speakers explore ideas on activism—what motivates it, why it matters, and how each of us can make a difference. Guests include civil rights activist Ruby Sales, labor leader and civil rights activist Dolores Huerta, author Jeremy Heimans, "craftivist" Sarah Corbett, and designer and futurist Angela Oguntala.
Now Playing: Science for the People

#520 A Closer Look at Objectivism
This week we broach the topic of Objectivism. We'll be speaking with Keith Lockitch, senior fellow at the Ayn Rand Institute, about the philosophy of Objectivism as it's taught through Ayn Rand's writings. Then we'll speak with Denise Cummins, cognitive scientist, author and fellow at the Association for Psychological Science, about the impact of Objectivist ideology on society. Related links: This is what happens when you take Ayn Rand seriously Another Critic Who Doesn’t Care What Rand Thought or Why She Thought It, Only That She’s Wrong Quote is from "A Companion to Ayn Rand"